Postmarketing experience with intermittent cyclical etidronate therapy

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 4, 1998, Pages 277-286

  Van Staa, T P ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

BONE BIOPSY; BONE MINERALIZATION; DIET SUPPLEMENTATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; ESOPHAGUS DISEASE; GASTROINTESTINAL TOXICITY; HIP FRACTURE; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK; RISK BENEFIT ANALYSIS;

EID: 0031835062     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Abdelmalek MF, Douglas DD. Alendronate-induced ulcerative esophagitis. Am J Gastroenterol 1996; 91: 1282-1283.
2. Adachi JD, Cranney A, Goldsmith CH et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss. J Rheumatol 1994; 21: 1922-1926.
3. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-387.
4. Adami S, Zamberlan N. Adverse effects of bisphosphonates. Drug Safety 1996; 14: 158-170.
5. Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326-331.
6. Adamson BR, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 1993; 342: 1459-1460.
7. Alexandre C, Tavin P, Chappard D, Pallot-Prades B, Prallet B, Riffat G. Intermittent administration of etidronate (Didronel) in involutional osteoporosis. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990, 3rd International Symposium on Osteoporosis. Aalborg: Handelsstrykkeriet Aalborg ApS, 1990: 1441-1443.
8. Gallacher SJ, Anderson K, Banham SW, Boyle IT. Bisphosphonate-induced bronchoconstriction in aspirin-sensitive asthma. Lancet 1994; 343: 924.
9. Geddes AD, Bevan JA, Kasting GB, Francis MD, Mosekilde L, Hasling C. Retention of bisphopshonate in bone: quantitation of etidronate in iliac-crest biopsy samples from patient on intermittent therapy for postmenopausal osteoporosis. J Bone Miner Res 1992; 7 (Suppl 1): S328.
10. Ghose K, Waterworth R, Trovlove P, Highton J. Uveitis associated with pamidronate. Aust N Z J Med 1994; 24: 320.
11. Girard M. Testing the methods of assessment for adverse drug reactions. Adv Drug React Acut Pois Rev 1984; 4: 237-244.